Related Experiment Video
Updated: Apr 30, 2026
09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
19.1K
High CD49f expression is associated with osteosarcoma tumor progression: a study using patient-derived primary cell
Patrice Penfornis1, David Z Cai, Michael R Harris
1Cancer Institute, University of Mississippi Medical Center, Jackson, Mississippi.
Cancer Medicine
|May 8, 2014
Summary
Researchers identified a specific cell surface marker, CD49f, crucial for osteosarcoma (OS) tumor growth. Inhibiting CD49f reduced tumor formation, suggesting it as a target for new osteosarcoma therapies.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Osteosarcoma (OS) has a poor prognosis despite aggressive treatments.
- Challenges in studying OS tumors and cell cultures limit understanding of its initiation and progression.
- CD49f is implicated in stemness and multipotency in cancer stem cells and mesenchymal stem cells.
Purpose of the Study:
- To isolate and characterize human osteosarcoma cell cultures.
- To investigate the role of CD49f in osteosarcoma progression and osteosarcomagenesis.
- To identify potential therapeutic targets for aggressive osteosarcoma.
Main Methods:
- Isolation and characterization of cell cultures from high-grade human OS samples.
- Analysis of cell surface marker expression (CD49f, CD90).
- Assessment of growth, differentiation, chemotherapy sensitivity, and anchorage-independent growth.
- Xenograft assays to evaluate tumor-forming ability.
Main Results:
- CD49f(hi)/CD90(lo) cell populations were associated with aggressive tumor formation in xenografts.
- Inhibition of CD49f significantly decreased tumor-forming capabilities.
- The CD49f(hi)/CD90(lo) phenotype indicates a more aggressive osteosarcoma tumor growth pattern.
Conclusions:
- CD49f plays a critical role in osteosarcoma tumor initiation and progression.
- The CD49f(hi)/CD90(lo) cell population represents a potential marker for aggressive osteosarcoma.
- Targeting CD49f may offer a novel therapeutic strategy for osteosarcoma treatment.
